Investigations into the potential effects of multiple dose ketorolac on the pharmacokinetics and pharmacodynamics of racemic warfarin.
1. The potential interaction between racemic warfarin given as a 25 mg single oral dose and chronically administered ketorolac was studied in 12 young healthy male volunteers. 2. Ketorolac produced no major change in the pharmacokinetics of (R)- or (S)-warfarin. 3. Ketorolac did not alter the pharmacodynamic profile of racemic warfarin. 4. Ketorolac increased template bleeding time by a factor of 1.35 as compared with placebo. 5. The results suggest that the ketorolac-warfarin interaction is unlikely to be of major clinical significance; however, combined use of ketorolac and warfarin in patients should be undertaken with due caution and appropriate monitoring.
Toon
S
S
Department of Pharmacy, University of Manchester.
Holt
B L
BL
Mullins
F G
FG
Bullingham
R
R
Aarons
L
L
Rowland
M
M
D000328:Adult; D000700:Analgesics / Q000008:administration & dosage* / Q000494:pharmacology; D001798:Blood Proteins / Q000378:metabolism; D004311:Double-Blind Method; D004347:Drug Interactions; D005167:Factor VII / Q000032:analysis; D006801:Humans; D007536:Isomerism; D020910:Ketorolac; D008297:Male; D008657:Metabolic Clearance Rate; D011517:Prothrombin Time; D014046:Tolmetin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D014859:Warfarin / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology*
D000700:Analgesics; D001798:Blood Proteins; D014859:Warfarin; D005167:Factor VII; D014046:Tolmetin; D020910:Ketorolac